Introduction Pharmacovigilance studies have definitely established that clozapine can cause
myocarditis. Two published reviews suggested that on rare occasions other antipsychotics …

Background Management of schizophrenia is sub-optimal in many patients. Targeting
negative symptoms, among the most debilitating aspects of schizophrenia, together with …

Current treatment standards in psychiatry are oriented towards polypharmacy, that is,
patients receive combinations of several antidepressants, antipsychotics, mood stabilizers …

Background: Dysfunction of the N-methyl-D-aspartate glutamate receptor is involved in the
putative pathology of schizophrenia. There is growing interest in the potential of N-methyl-D …

Background: Cariprazine, a novel antipsychotic drug, is a partial agonist of dopamine D2/D3
receptors with preferential binding to the D3 receptor. There has been an increasing interest …

Background Antipsychotic polypharmacy (APP) is frequently prescribed for schizophrenia-
spectrum disorders. Despite the inconsistent findings on efficacy, APP may be beneficial for …

Objectives: To investigate the differences in psychotic symptoms and cognitive function in
schizophrenics with and without depression and to compare gender differences in the …

Antipsychotic polypharmacy (APP) in patients with schizophrenia spectrum disorders (SSDs)
is usually not recommended, though it is very common in clinical practice. Both APP and …

Introduction Antipsychotic polypharmacy (APP), defined as the use of more than one
antipsychotic, is common in schizophrenia. However, current guidelines consider that the …

Background Antipsychotic polypharmacy (APP) is frequent but evidence-based guidelines
on reducing APP to antipsychotic monotherapy (APM) are sparse. We aimed to …